NCT01611571View on ClinicalTrials.gov

Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Osteoporosis
Interventions
DRUG

Risedronate

weekly risedronate

DRUG

Teriparatide

daily teriparatide

DRUG

Placebo Teriparatide

daily placebo of teriparatide

DRUG

placebo Risedronate

weekly placebo of Risedronic Acid

Trial Locations (1)

10032

Columbia University Medical Center, Harkness Pavilion, New York

All Listed Sponsors
collaborator

Alliance for Better Bone Health

OTHER

lead

Columbia University

OTHER

NCT01611571 - Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis | Biotech Hunter | Biotech Hunter